CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Cytori Therapeutics - PSTV CFD

    1.65
    5.17%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 1.74
    Open* 1.8
    1-Year Change* 361.54%
    Day's Range* 1.64 - 1.89
    52 wk Range 0.97-7.20
    Average Volume (10 days) 235.95K
    Average Volume (3 months) 14.59M
    Market Cap 8.28M
    P/E Ratio -100.00K
    Shares Outstanding 4.52M
    Revenue 3.75M
    EPS -6.18
    Dividend (Yield %) N/A
    Beta 0.66
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 29, 2023 1.65 -0.15 -8.33% 1.80 1.89 1.64
    Nov 28, 2023 1.74 0.04 2.35% 1.70 1.76 1.70
    Nov 27, 2023 1.67 0.08 5.03% 1.59 1.78 1.59
    Nov 24, 2023 1.61 -0.09 -5.29% 1.70 1.76 1.60
    Nov 22, 2023 1.79 0.05 2.87% 1.74 1.86 1.74
    Nov 21, 2023 1.79 -0.03 -1.65% 1.82 1.82 1.69
    Nov 20, 2023 1.85 -0.23 -11.06% 2.08 2.46 1.64
    Nov 17, 2023 2.59 0.24 10.21% 2.35 2.72 2.13
    Nov 16, 2023 2.15 0.28 14.97% 1.87 2.20 1.85
    Nov 15, 2023 1.86 0.24 14.81% 1.62 1.88 1.62
    Nov 14, 2023 1.66 0.26 18.57% 1.40 1.71 1.40
    Nov 13, 2023 1.43 0.03 2.14% 1.40 1.45 1.37
    Nov 10, 2023 1.37 -0.07 -4.86% 1.44 1.48 1.35
    Nov 9, 2023 1.47 -0.10 -6.37% 1.57 1.59 1.44
    Nov 8, 2023 1.56 -0.12 -7.14% 1.68 1.68 1.53
    Nov 7, 2023 1.63 0.11 7.24% 1.52 1.66 1.52
    Nov 6, 2023 1.58 0.12 8.22% 1.46 1.59 1.42
    Nov 3, 2023 1.56 0.07 4.70% 1.49 1.64 1.36
    Nov 2, 2023 1.34 0.11 8.94% 1.23 1.51 1.21
    Nov 1, 2023 1.25 -0.05 -3.85% 1.30 1.33 1.19

    Cytori Therapeutics Events

    Time (UTC) Country Event
    Tuesday, December 5, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Plus Therapeutics Inc at San Antonio Breast Cancer Symposium
    Plus Therapeutics Inc at San Antonio Breast Cancer Symposium

    Forecast

    -

    Previous

    -
    Wednesday, February 21, 2024

    Time (UTC)

    15:00

    Country

    US

    Event

    Q4 2023 Plus Therapeutics Inc Earnings Release
    Q4 2023 Plus Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, April 18, 2024

    Time (UTC)

    14:00

    Country

    US

    Event

    Q1 2024 Plus Therapeutics Inc Earnings Release
    Q1 2024 Plus Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Friday, April 19, 2024

    Time (UTC)

    14:00

    Country

    US

    Event

    Plus Therapeutics Inc Annual Shareholders Meeting
    Plus Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.224 0 0.303 6.998 6.654
    Revenue 0.224 0 0.303 6.998 6.654
    Cost of Revenue, Total 2.373
    Gross Profit 4.281
    Total Operating Expense 19.936 12.492 9.887 10.655 19.352
    Selling/General/Admin. Expenses, Total 10.238 6.853 6.406 5.29 8.357
    Research & Development 9.698 5.323 2.7 5.365 8.622
    Interest Expense (Income) - Net Operating
    Unusual Expense (Income) 0 0.316 0.781 0
    Operating Income -19.712 -12.492 -9.584 -3.657 -12.698
    Interest Income (Expense), Net Non-Operating -0.563 -0.907 1.343 1.607 0.354
    Other, Net 0 -1.233 -0.29
    Net Income Before Taxes -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income After Taxes -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income Before Extra. Items -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income -20.275 -13.399 -8.241 -10.887 -12.634
    Total Adjustments to Net Income 0 -0.554 -2.487
    Income Available to Common Excl. Extra. Items -20.275 -13.399 -8.241 -3.837 -15.121
    Income Available to Common Incl. Extra. Items -20.275 -13.399 -8.241 -11.441 -15.121
    Diluted Net Income -20.275 -13.399 -8.241 -11.441 -15.121
    Diluted Weighted Average Shares 1.75035 0.80599 0.2952 0.09227 0.01159
    Diluted EPS Excluding Extraordinary Items -11.5834 -16.6244 -27.9163 -41.5835 -1304.59
    Diluted Normalized EPS -11.5834 -16.2323 -25.2707 -41.5835 -1304.59
    Total Extraordinary Items 0 -7.604
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1.854 0.506 0.151 0.073 0
    Revenue 1.854 0.506 0.151 0.073
    Total Operating Expense 3.344 5.226 5.723 5.167 5.12
    Selling/General/Admin. Expenses, Total 1.924 2.243 3.585 2.222 2.289
    Research & Development 1.42 2.983 2.138 2.945 2.831
    Operating Income -1.49 -4.72 -5.572 -5.094 -5.12
    Interest Income (Expense), Net Non-Operating 0.008 -0.083 -0.086 -0.125 -0.162
    Net Income Before Taxes -1.482 -4.805 -5.658 -5.219 -5.282
    Net Income After Taxes -1.482 -4.805 -5.658 -5.219 -5.282
    Net Income Before Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
    Net Income -1.482 -4.805 -5.658 -5.219 -5.282
    Income Available to Common Excl. Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
    Income Available to Common Incl. Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
    Diluted Net Income -1.482 -4.805 -5.658 -5.219 -5.282
    Diluted Weighted Average Shares 2.50938 2.32013 2.24356 1.82954 1.48373
    Diluted EPS Excluding Extraordinary Items -0.59058 -2.071 -2.52188 -2.85264 -3.55995
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.59058 -2.07014 -2.52188 -2.85264 -3.55995
    Unusual Expense (Income) 0 0
    Gain (Loss) on Sale of Assets 0 -0.002
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 21.817 19.724 9.175 19.825 9.648
    Cash and Short Term Investments 18.12 18.4 8.346 17.552 5.261
    Cash & Equivalents 18.12 18.4 8.346 17.552 5.261
    Total Receivables, Net 0 1.313 0.178
    Accounts Receivable - Trade, Net 0 1.169 0.178
    Total Inventory 0 0.107 0.107
    Other Current Assets, Total 0.007 0.059 0.04 4.102
    Total Assets 23.867 21.981 12.105 23.229 23.991
    Property/Plant/Equipment, Total - Net 1.572 1.818 2.456 2.96 2.299
    Goodwill, Net 0.372 0.372 0.372 0.372 0.372
    Intangibles, Net 0.094 0.051 0.086
    Other Long Term Assets, Total 0.012 0.016 0.016 0.072 11.672
    Total Current Liabilities 11.852 5.87 8.539 14.486 17.559
    Payable/Accrued 0.245 2.777
    Notes Payable/Short Term Debt 1.608 1.608 6.335 0 14.202
    Current Port. of LT Debt/Capital Leases 0 0 0.01 11.18
    Total Liabilities 17.422 11.145 9.074 22.069 18.766
    Total Long Term Debt 3.786 5.005 0 0.008 0
    Long Term Debt 3.786 5.005
    Other Liabilities, Total 1.784 0.27 0.535 7.575 1.207
    Total Equity 6.445 10.836 3.031 1.16 5.225
    Preferred Stock - Non Redeemable, Net 0 0
    Common Stock 0.034 0.016 0.007 0.004 0
    Additional Paid-In Capital 473.596 457.73 436.535 426.426 418.39
    Retained Earnings (Accumulated Deficit) -467.185 -446.91 -433.511 -425.27 -414.383
    Other Equity, Total 0 1.218
    Total Liabilities & Shareholders’ Equity 23.867 21.981 12.105 23.229 23.991
    Total Common Shares Outstanding 2.2402 1.03405 0.44996 0.25872 0.01977
    Property/Plant/Equipment, Total - Gross 3.532 3.233 3.843 3.981 0
    Accrued Expenses 1.88 1.529 1.137 2.973 0
    Other Current Liabilities, Total 0 0.122 0.023 0.006 0.58
    Prepaid Expenses 3.697 1.317 0.77 0.813
    Accumulated Depreciation, Total -1.96 -1.415 -1.387 -1.021
    Accounts Payable 8.364 2.611 0.789 0.327
    Capital Lease Obligations 0 0.008
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 11.584 12.364 13.629 21.817 20.879
    Cash and Short Term Investments 11.006 10.895 12.723 18.12 20.266
    Cash & Equivalents 11.006 10.895 12.723 18.12 20.266
    Other Current Assets, Total 0.487 0.751 0.906 3.697 0.54
    Total Assets 13.278 14.197 15.638 23.867 23.104
    Property/Plant/Equipment, Total - Net 1.241 1.385 1.546 1.572 1.728
    Goodwill, Net 0.372 0.372 0.372 0.372 0.372
    Intangibles, Net 0.049 0.064 0.079 0.094 0.113
    Other Long Term Assets, Total 0.032 0.012 0.012 0.012 0.012
    Total Current Liabilities 10.538 11.399 12.796 11.852 7.42
    Payable/Accrued 6.073 6.58 6.495 10.134 5.705
    Accrued Expenses 0.117 0.11 0.107 0.11 0.107
    Notes Payable/Short Term Debt 4.348 4.709 5.057 1.608 1.608
    Current Port. of LT Debt/Capital Leases 0
    Total Liabilities 10.656 11.535 12.962 17.422 11.7
    Total Long Term Debt 0 0 0 3.786 4.108
    Capital Lease Obligations
    Other Liabilities, Total 0.118 0.136 0.166 1.784 0.172
    Total Equity 2.622 2.662 2.676 6.445 11.404
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 0.005 0.003 0.036 0.034 0.032
    Additional Paid-In Capital 479.308 476.131 474.63 473.596 472.899
    Retained Earnings (Accumulated Deficit) -476.691 -473.472 -471.99 -467.185 -461.527
    Total Liabilities & Shareholders’ Equity 13.278 14.197 15.638 23.867 23.104
    Total Common Shares Outstanding 4.52266 2.87962 2.40838 2.2402 2.17144
    Long Term Debt 0 0 0 3.786 4.108
    Total Receivables, Net 0.091 0.718 0.073
    Other Current Liabilities, Total 1.137
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -20.275 -13.399 -8.241 -10.887 -12.634
    Cash From Operating Activities -12.972 -10.28 -8.434 -5.906 -11.975
    Cash From Operating Activities 0.619 0.395 0.366 0.896 2.004
    Non-Cash Items 0.958 1.486 -0.678 5.023 -0.313
    Cash Interest Paid 0.327 0.388 0.567 1.188 1.331
    Changes in Working Capital 5.726 1.238 0.119 -0.938 -1.032
    Cash From Investing Activities -0.759 -0.082 -0.493 5.57 -0.133
    Capital Expenditures -0.509 -0.144 -0.493 -0.067 -0.133
    Other Investing Cash Flow Items, Total -0.25 0.062 0 5.637 0
    Cash From Financing Activities 13.451 20.416 -0.319 12.631 7.168
    Financing Cash Flow Items 0 -1.598
    Total Cash Dividends Paid
    Issuance (Retirement) of Stock, Net 15.059 20.692 5.105 16.454 8.766
    Issuance (Retirement) of Debt, Net -1.608 -0.276 -5.424 -3.823 0
    Foreign Exchange Effects 0 -0.004 0.016
    Net Change in Cash -0.28 10.054 -9.246 12.291 -4.924
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.805 -20.275 -14.617 -9.398 -4.116
    Cash From Operating Activities -5.793 -12.972 -10.738 -6.516 -3.876
    Cash From Operating Activities 0.158 0.619 0.46 0.302 0.147
    Non-Cash Items 0.208 0.958 0.749 0.528 0.284
    Cash Interest Paid 0.073 0.327 0.248 0.168 0.087
    Changes in Working Capital -1.354 5.726 2.67 2.052 -0.191
    Cash From Investing Activities -0.097 -0.759 -0.748 -0.715 -0.577
    Capital Expenditures -0.097 -0.509 -0.498 -0.465 -0.327
    Cash From Financing Activities 0.493 13.451 13.352 6.921 7.292
    Issuance (Retirement) of Stock, Net 0.895 15.059 14.558 7.725 7.694
    Issuance (Retirement) of Debt, Net -0.402 -1.608 -1.206 -0.804 -0.402
    Net Change in Cash -5.397 -0.28 1.866 -0.31 2.839
    Other Investing Cash Flow Items, Total 0 -0.25 -0.25 -0.25 -0.25

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Cytori Therapeutics Company profile

    About Plus Therapeutics Inc

    Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).

    Equity composition

    Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.

    Industry: Biotechnology & Medical Research (NEC)

    4200 Marathon Blvd Ste 200
    AUSTIN
    TEXAS 78756-3433
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    BTC/USD

    38,042.65 Price
    +0.070% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    78.12 Price
    +1.990% 1D Chg, %
    Long position overnight fee -0.0164%
    Short position overnight fee -0.0055%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    2,044.94 Price
    +0.170% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    16,023.40 Price
    +0.090% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading